0       0

2015 ISHLT Annual Meeting and Scientific Sessions


CCS11f - CONCURRENT SESSION 11: New Tools in the Fight Against Rejection -- The Effect of Everolimus Initiation and Calcineurin Inhibitor Reduction on Allograft Vasculopathy in Maintenance Heart Transplant Recipients: Results of the NOCTET Trial After 5 Years


Apr 16, 2015 3:45pm ‐ Apr 16, 2015 4:00pm

Description

Presentation Includes
 

  • Plasmapheresis and Bortezomib for Sensitized Patients Awaiting Heart Transplantation - Worth the Effort?
  • Terminal Complement Inhibition for Highly Sensitized Patients Undergoing Heart Transplantation - Doable?
  • Personalized Therapeutic Use of Intravenous Immunoglobulin in Heart Recipients With Severe Infections and IgG Hypogammaglobulinemia: Impact on Clinical Outcomes
  • Increased Plasma Levels of Donor-Derived Cell-Free DNA Correlate With Rejection in Heart Transplant Recipients: The CARGO II Multicenter Trial
  • Multicentre Study to Evaluate Conversion From Standard-Release Tacrolimus (SRT) to Extended-Release Tacrolimus (ERT) in a Large Series of Heart Transplanted Patients
  • The Effect of Everolimus Initiation and Calcineurin Inhibitor Reduction on Allograft Vasculopathy in Maintenance Heart Transplant Recipients: Results of the NOCTET Trial After 5 Years

Speaker(s):

  • Satish Arora, MD, PhD, Oslo University Hospital, Oslo, Norway

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content